Skip to main content

Table 1 Demographics and baseline characteristics of patients in the MEASURE 1 and ENRADAS cohorts

From: Spinal radiographic progression over 2 years in ankylosing spondylitis patients treated with secukinumab: a historical cohort comparison

   MEASURE 1   ENRADAS
Characteristic Primary Analysis Set (N = 168)a Sensitivity Analysis Set 1 (N = 175)b Sensitivity Analysis Set 2 (N = 201) Primary Analysis Set (N = 69)a Sensitivity Analysis Set 1 (N = 78)b Sensitivity Analysis Set 2 (N = 122)
mSASSS 9.6 ± 14.1 9.0 ± 14.05 6.4 ± 10.4 9.9 ± 13.8 9.8 ± 13.3 7.9 ± 10.5
CRP (mg/L) 18.3 ± 23.4 18.1 ± 22.1 17.5 ± 21.1 8.8 ± 9.7 10.1 ± 11.5 10.1 ± 12.0
Smoker, n (%) 42 (25.0) 33 (18.9) 45 (22.4) 31 (44.9) 35 (44.9) 56 (46.3)
Time since diagnosis, years 7.2 ± 8.0 6.3 ± 7.0 6.9 ± 7.7 10.3 ± 11.1 8.9 ± 10.5 8.6 ± 10.1
NSAID use, n (%) 166 (98.8) 174 (99.4) 199 (99.0) 69 (100) 78 (100) 122 (100)
Corticosteroid use, n (%) 23 (13.7) 23 (13.1) 26 (12.9) Not available Not available 78 (63.9)c
Age in years 41.0 ± 12.6 40.3 ± 12.8 41.3 ± 12.6 42.6 ± 10.8 42.0 ± 10.4 42.8 ± 10.2
Male, n (%) 123 (73.2) 122 (69.7) 141 (70.1) 46 (66.7) 56 (71.8) 84 (68.9)
HLA-B27 positive, n (%) 136 (82.9) 139 (81.8) 155 (79.5) 61 (88.4) 72 (92.3) 110 (90.2)
  1. Data are mean ± standard deviation unless otherwise stated
  2. CRP C-reactive protein, ENRADAS effects of nonsteroidal anti-inflammatory drugs (NSAIDs) on Radiographic Damage in Ankylosing Spondylitis, HLA human leukocyte antigen, mSASSS modified Stoke Ankylosing Spondylitis Spinal Score, NSAID nonsteroidal anti-inflammatory drugs
  3. aData are shown for patients with baseline and days 31–743 radiographs
  4. bData are shown for patients with baseline and days 640–819 radiographs
  5. cCorticosteroid use from the total ENRADAS study population—personal communication from D Poddubnyy